Daniel Lyons, Ph.D., CFA
Daniel Lyons is a Portfolio Manager and Research Analyst at Janus Henderson Investors responsible for co-managing the Biotechnology strategy since 2018. Dr. Lyons started consulting for Janus in 1997 and joined the Health Care Sector Research Team full time in 2000. As a research analyst, he focuses on the biotechnology and life science tools sectors.
Dr. Lyons received his bachelor of arts degree in biochemistry and chemistry from Rice University, graduating magna cum laude. He also earned a Ph.D. from Stanford University’s program in immunology and conducted postdoctoral research with a Nobel Laureate at the University of Colorado. He holds the Chartered Financial Analyst designation and has 20 years of financial industry experience.
Articles Written
What a Return to “Normal” Could Mean for Equities
In our ongoing video series on COVID-19, a discussion of the pandemic’s trajectory, vaccine development and investment considerations post-crisis.
COVID-19: Understanding the Science & Investment Implications (Part IV)
A new video series from our health care team offers unique insight into the scientific and investment implications of the COVID-19 crisis.
Taking a Balanced Approach to Investing in Cancer Therapy
There’s more than one way to gain exposure to advances in oncology, say Andy Acker, Dan Lyons and Luyi Guo of the Global Life Sciences Team.